FinanceET Techabout 3 hours ago
Zydus shares fall 2% on $166M Assertio buy
2 min read
Zydus Lifesciences shares fell 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity and strengthens Zydus's specialty and oncology supportive-care therapies pipeline.
Level
Hype check
Tap to vote and see what everyone thinks.
